Celebrating the Grand Success of "Heer Medical New Product Technology Launch Conference"

On November 11–12, 2017, Wuhan Heer Medical Technology Development Co., Ltd. held the "Heer Medical New Product Technology Launch Conference" at the Wuhan High-Speed Rail Carre International Hotel. The conference invited Prof. Christof Sohn, Director of the Department of Obstetrics and Gynecology at Heidelberg University Hospital, Academician Fan Daiming, Vice President of the Chinese Academy of Engineering, Prof. Liu Dongge, Vice Chairman of the Pathology Branch of the Chinese Medical Association, and many other top domestic and international experts, along with over 200 guests.

As a wholly owned subsidiary of Xinkaiyuan Group, Heer Medical has, over more than 10 years of innovation and progress, built a comprehensive product line centered on the DNA quantitative intelligent analysis system, complemented by slide preparation machines, fully automated staining machines, HIS systems, and cloud platform services. Heer Medical operates an independent production facility, R&D building, office building, and Heer Medical Laboratory. The company has recently launched a multispectral DNA quantitative analysis system and HPV E6E7 protein detection technology. Through domestic and international collaboration, Heer Medical has partnered with the Karolinska Institute in Sweden on a liquid biopsy project for breast cancer, successfully acquired pyrosequencing technology and patents from Feist, and partnered with Heidelberg University Hospital to build a liquid screening platform for breast cancer — becoming the first Chinese company to directly collaborate with Heidelberg University Hospital.

At this conference, Heer Medical launched the "AI-Integrated Cervical Cancer Screening Solution." Building on the fully automated DNA quantitative analysis system with complete independent intellectual property rights and invention patents, the solution integrates multispectral re-staining technology, HPV-E6E7 oncoprotein detection technology, cloud intelligent storage and computing, big data analysis, and automated slide preparation and staining equipment. This all-new integrated AI solution for cervical cancer screening fully resolves numerous challenges in the screening workflow while achieving automation, intelligence, high sensitivity, and high specificity in detection methods.

The new instruments and technologies attracted intense interest from guests, sparking lively discussion and consultation on the spot.

After the conference, guests were invited to tour the company's standardized laboratory and modern production workshop. Heer Medical's innovative technology, advanced diagnostics, comprehensive after-sales service, and the warmth of the Heer team received unanimous praise from all attendees.